SCHEMBL4418919

SCHEMBL4418919

CC(C)(C)c1ccc(CN2CC3C(CNC(=O)c4ccc(N5CCCC5=O)cc4)C3C2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.53
HSD17B10 Q99714 1/20 0.52
LMNA P02545 4/20 0.51
ALDH1A1 P00352 5/20 0.49
POLB P06746 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
MEN1 O00255 1/20 0.48
BLM P54132 1/20 0.48
KMT2A Q03164 1/20 0.48
HPGD P15428 4/20 0.48
RECQL P46063 1/20 0.48
TSHR P16473 3/20 0.47
GALR3 O60755 1/20 0.47
HTT P42858 1/20 0.47
F10 P00742 1/20 0.46
RAB9A P51151 2/20 0.46
KDM4E B2RXH2 1/20 0.46
NAMPT P43490 1/20 0.45
CYP1A2 P05177 2/20 0.45
NPC1 O15118 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4421379 0.87 HSD17B10 (0.53) MAPTHSD17B10LMNAALDH1A1POLB
SCHEMBL4418921 0.86 F10 (0.42) MAPTHSD17B10LMNAALDH1A1SMN1; SMN2
SCHEMBL4421597 0.84 AKR1C3 (0.51) MAPTHSD17B10LMNAALDH1A1MEN1
SCHEMBL4412087 0.82 MAPT (0.57) MAPTLMNAALDH1A1SMN1; SMN2MEN1
SCHEMBL4425012 0.77 ALDH1A1 (0.53) MAPTALDH1A1POLBSMN1; SMN2MEN1
SCHEMBL4421382 0.77 HPGD (0.49) MAPTHSD17B10LMNAALDH1A1SMN1; SMN2
SCHEMBL4413490 0.76 KDM4E (0.45) MAPTALDH1A1MEN1KMT2ARAB9A
SCHEMBL4417470 0.75 OPRM1 (0.44) MAPTHSD17B10LMNAALDH1A1SMN1; SMN2
SCHEMBL2183275 0.74 F10 (0.42) MAPTLMNAMEN1KMT2AHPGD
SCHEMBL4430223 0.74 HRH3 (0.52) MAPTALDH1A1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP claimed
EP-1680124-A4 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2009-05-13 EP claimed
JP-2007508374-A 2007-04-05 JP claimed
EP-1680124-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS Pfizer Products Incorporated (US) 2006-07-19 EP claimed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US claimed
WO-2005037216-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PRODUCTS INC. (US) 2005-04-28 WO claimed
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP disclosed
US-7473787-B2 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC (US) 2009-01-06 US disclosed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors SLC6A5, SLC1A5, SLC6A3 MAPT 1368/4885HSD17B10 2567/4885LMNA 4565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.